| Name | Suberoyl bis-hydroxamic acid |
| Description | Suberoyl bis-hydroxamic acid (SBHA) is a Histone deacetylase (HDAC) inhibitor. HDAC is required for transcriptional modulation, cell cycle regulation and development. It is an enzyme that deacetylates lysine residues on the N-terminal of the core histones. |
| In vitro | In MEL cells, SBHA leads to the accumulation of acetylated H4, indicating the hydroxamic acid groups are involved in increasing potency and inhibition of HDAC activity. In Jurkat cells, SHBA inhibits the HDAC1 and HDAC3 activities with IC50 value of 0.25 and 0.3 μm respectively. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (9.79 mM), Sonication is recommended. H2O : 8.16 mg/mL (39.96 mM), Sonication is recommended. DMSO : 49 mg/mL (239.94 mM), Sonication is recommended.
|
| Keywords | thyroid | Suberoyl bis-hydroxamic acid | Suberoyl bishydroxamic acid | Suberoyl bis hydroxamic acid | neuroendocrine malignancy | neoplastic disease | neoplasia | MTC | mesothelioma | Medullary | Malignant | Inhibitor | inhibit | Histone deacetylases | HDAC3 | HDAC1 | HDAC | carcinoma | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Manganese chloride (tetrahydrate) | Formamide | Dimethyl phthalate | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Histone Modification Compound Library | Epigenetics Compound Library | HIF-1 Signaling Pathway Compound Library | Chromatin Modification Compound Library | Post-Translational Modification Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |